Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEAMERICAN:AMS NASDAQ:BDSX NASDAQ:NAKA NASDAQ:PIII On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMSAmerican Shared Hospital Services$2.59+0.4%$2.49$2.27▼$4.60$16.64M0.314,546 shs1,617 shsBDSXBiodesix$0.40+3.5%$0.33$0.17▼$2.04$56.23M0.991.55 million shs853,885 shsNAKAKindlyMD$15.02+13.4%$12.15$0.65▼$34.77$100.78M34.35554,710 shs885,260 shsPIIIP3 Health Partners$6.94-2.3%$6.59$5.80▼$30.49$51.03M0.8112,575 shs4,134 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMSAmerican Shared Hospital Services+0.39%+4.44%+6.58%+0.78%-3.36%BDSXBiodesix+3.52%-11.19%+29.65%+31.81%-76.92%NAKAKindlyMD+13.36%+100.27%+27.61%+1,501,999,900.00%+1,501,999,900.00%PIIIP3 Health Partners+0.80%+1.61%+9.29%-13.14%-76.47%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMSAmerican Shared Hospital Services1.2239 of 5 stars0.03.00.00.03.31.70.6BDSXBiodesix3.189 of 5 stars3.45.00.00.01.52.50.6NAKAKindlyMDN/AN/AN/AN/AN/AN/AN/AN/APIIIP3 Health Partners2.361 of 5 stars3.32.00.00.02.40.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMSAmerican Shared Hospital Services 0.00N/AN/AN/ABDSXBiodesix 2.80Moderate Buy$1.75340.81% UpsideNAKAKindlyMD 0.00N/AN/AN/APIIIP3 Health Partners 2.50Moderate Buy$16.25134.15% UpsideCurrent Analyst Ratings BreakdownLatest AMS, BDSX, NAKA, and PIII Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025BDSXBiodesixScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$3.00 ➝ $2.00(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMSAmerican Shared Hospital Services$28.34M0.59$0.89 per share2.91$4.68 per share0.55BDSXBiodesix$71.32M0.82N/AN/A$0.01 per share39.70NAKAKindlyMD$2.72M42.02N/AN/A$1.18 per share12.73PIIIP3 Health Partners$1.50B0.03N/AN/A$10.58 per share0.66Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMSAmerican Shared Hospital Services$2.19M$0.60N/A8.63N/A-8.27%-7.97%-3.89%N/ABDSXBiodesix-$42.93M-$0.29N/AN/AN/A-53.66%-269.67%-43.94%N/ANAKAKindlyMD-$3.62M-$0.86N/A∞N/A-244.00%-131.09%-106.04%N/APIIIP3 Health Partners-$135.85M-$47.28N/AN/AN/A-9.27%-123.10%-15.94%N/ALatest AMS, BDSX, NAKA, and PIII EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025PIIIP3 Health Partners-$3.29-$6.23-$2.94-$6.23$356.52 million$355.79 million8/7/2025Q2 2025BDSXBiodesix-$0.07-$0.08-$0.01-$0.08$18.47 million$20.02 million8/5/2025Q2 2025NAKAKindlyMDN/A-$0.34N/A-$0.35N/A$0.41 million5/15/2025Q1 2025PIIIP3 Health Partners-$5.00-$6.28-$1.28-$6.28$362.09 million$373.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMSAmerican Shared Hospital ServicesN/AN/AN/AN/AN/ABDSXBiodesixN/AN/AN/AN/AN/ANAKAKindlyMDN/AN/AN/AN/AN/APIIIP3 Health PartnersN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMSAmerican Shared Hospital Services0.581.871.87BDSXBiodesix41.112.142.22NAKAKindlyMDN/A13.0013.00PIIIP3 Health Partners1.680.380.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMSAmerican Shared Hospital Services23.16%BDSXBiodesix20.96%NAKAKindlyMDN/APIIIP3 Health Partners7.75%Insider OwnershipCompanyInsider OwnershipAMSAmerican Shared Hospital Services23.80%BDSXBiodesix30.10%NAKAKindlyMD40.79%PIIIP3 Health Partners17.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMSAmerican Shared Hospital Services106.45 million4.92 millionNot OptionableBDSXBiodesix220146.63 million102.50 millionOptionableNAKAKindlyMDN/A7.61 million4.50 millionN/APIIIP3 Health Partners5007.19 million5.91 millionNot OptionableAMS, BDSX, NAKA, and PIII HeadlinesRecent News About These CompaniesP3 Health Partners Inc. (PIII) Q2 2025 Earnings Call Transcript4 hours ago | seekingalpha.comP3 Health Partners Inc. (PIII) Reports Q2 Loss, Lags Revenue EstimatesAugust 14 at 6:15 PM | zacks.comP3 Health Partners Announces Second Quarter 2025 ResultsAugust 14 at 4:05 PM | businesswire.comP3 Health Partners (PIII) Expected to Announce Earnings on ThursdayAugust 13 at 2:21 AM | americanbankingnews.comP3 Health Partners Schedules Second Quarter 2025 Earnings Release and Conference CallJuly 31, 2025 | businesswire.comP3 Health Partners (PIII) Projected to Post Quarterly Earnings on WednesdayJuly 30, 2025 | marketbeat.comWolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.July 28, 2025 | globenewswire.comWolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.July 22, 2025 | globenewswire.comP3 Health Partners Inc. (PIII) - Yahoo FinanceJuly 2, 2025 | finance.yahoo.comWolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.June 16, 2025 | globenewswire.comBears are Losing Control Over P3 Health Partners (PIII), Here's Why It's a 'Buy' NowJune 12, 2025 | zacks.comWolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.June 6, 2025 | globenewswire.comWolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.June 3, 2025 | globenewswire.comWolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.May 27, 2025 | globenewswire.comDown 18.4% in 4 Weeks, Here's Why You Should You Buy the Dip in P3 Health Partners (PIII)May 26, 2025 | zacks.comWolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.May 23, 2025 | globenewswire.comP3 Health Partners Inc. (NASDAQ:PIII) Q1 2025 Earnings Call TranscriptMay 17, 2025 | msn.comP3 Health Partners Inc (PIII) Q1 2025 Earnings Report Preview: What To Look ForMay 16, 2025 | finance.yahoo.comP3 Health Partners Inc (PIII) Q1 2025 Earnings Call Highlights: Strategic Adjustments and ...May 16, 2025 | finance.yahoo.comP3 Health Partners reaffirms $130M EBITDA improvement plan as operational initiatives accelerate in 2025May 16, 2025 | msn.comP3 Health Partners Inc. (PIII) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWhy the American Eagle Stock Rally Isn't Just Speculation By Gabriel Osorio-Mazilli | July 28, 2025Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli LillyBy Jordan Chussler | August 9, 2025Tesla Teams With Samsung—Will Other Chipmakers Follow?By Gabriel Osorio-Mazilli | August 1, 2025Newmont's Financial Strength Sets a High Bar for Gold MinersBy Jeffrey Neal Johnson | August 1, 20253 Natural Gas Stocks Powering the AI Data Center BoomBy Chris Markoch | August 11, 2025AMS, BDSX, NAKA, and PIII Company DescriptionsAmerican Shared Hospital Services NYSEAMERICAN:AMS$2.59 +0.01 (+0.39%) Closing price 08/14/2025 04:10 PM EasternExtended Trading$2.57 -0.02 (-0.77%) As of 08/14/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.American Shared Hospital Services provides stereotactic radiosurgery and advanced radiation therapy equipment. It operates in two segments, Medical Equipment Leasing, and Retail. The company offers radiosurgery equipment for the Gamma Knife stereotactic radiosurgery, a non-invasive procedure to treat malignant and benign brain tumors, and arteriovenous malformations, as well as for trigeminal neuralgia. It also provides financing services for Leksell Gamma Knife units; and leases medical equipment. In addition, the company offers proton beam radiation therapy services in Orlando, Florida and Long Beach, California, as well as offers planning, installation, reimbursement, and marketing support services to its customers. The company markets its solutions to cancer treatment centers, hospitals, and cancer networks worldwide. American Shared Hospital Services was founded in 1980 and is based in San Francisco, California.Biodesix NASDAQ:BDSX$0.40 +0.01 (+3.52%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$0.39 0.00 (-1.01%) As of 08/14/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.KindlyMD NASDAQ:NAKA$15.02 +1.77 (+13.36%) As of 08/14/2025 04:00 PM EasternKindly MD, Inc. (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, trauma and addiction therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, medically managed weight loss, and hormone therapy. Through its focus on an embedded model of prescriber and therapist teams, KindlyMD develops patient-specific care programs with a specific mission to reduce opioid use in the patient population while successfully treating patients with effective and evidence-based non-opioid alternatives in close conjunction with behavioral therapy. Beyond its treatment of patients, KindlyMD collects data focused on why and how patients turn to alternative treatments to reduce prescription medication use and addiction. The Company captures all relevant datapoints to assist and appropriately treat each individual patient. This also results in valuable data for the Company and the Company’s investors. We strive to become a source for evidence-based guidelines, data, treatment models, and education in the fight against the opioid crisis in America. Business Revenue Streams We currently earn revenue through (i) patient care services related to medical evaluation and treatment and (ii) product retail sales. Our forecasted plan is to operate across various revenue streams: (i) medical evaluation and treatment visits reimbursed by Medicare, Medicaid, and commercial insurance payers as well as self-pay services, (ii) data collection and research, (iii) education partnerships, (iv) service affiliate agreements, and (v) retail sales. Our principal executive offices are located at 5097 S 900 E, Suite 100 Salt Lake City, UT.P3 Health Partners NASDAQ:PIII$6.94 -0.16 (-2.25%) Closing price 08/14/2025 03:56 PM EasternExtended Trading$6.66 -0.28 (-4.03%) As of 08/14/2025 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Deere’s Sell-Off Could Be a Long-Term Buying Chance Cisco Systems: The Only AI Stock Income Investors Need to Own Gartner’s RSI Just Sank to 11: That’s a Setup You Can’t Ignore How Did Peter Thiel-Backed Crypto Exchange Bullish's IPO Go? Mercury Systems Up 27%: Financials Send Investors a Clear Signal Brinker Serves Up Earnings Beat, Sidesteps Cost Pressures CAVA’s Honeymoon Ends With a 16% Stock Drop Rigetti Stock: A Long-Term Quantum Play Facing Short-Term Tests Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access